OpenAI put GPT-Rosalind into research preview for qualified life-science teams, pairing a domain model with a Codex plugin that connects to more than 50 tools and data sources. The strongest signal is not the branding: OpenAI says best-of-ten submissions ranked above the 95th percentile of human experts on one Dyno Therapeutics RNA prediction task.
Roche says it is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on-premises sites in the U.S. and Europe. The company says the new AI factory backbone will support biological foundation models, faster drug discovery, digital twins for manufacturing, and broader AI use across diagnostics and digital health.
NVIDIA says Lilly has brought LillyPod online, a pharma-owned AI factory built with 1,016 Blackwell Ultra GPUs and more than 9,000 petaflops of AI performance. The platform is intended to accelerate model training and simulation across genomics, small molecules, and clinical-development workflows.
Isomorphic Labs, the DeepMind spin-off focused on AI-driven drug discovery, has unveiled a new AI that scientists are calling a generational leap comparable to AlphaFold.
Google DeepMind spin-off Isomorphic Labs published a technical report on IsoDDE, a proprietary drug discovery AI that scientists are comparing to a hypothetical AlphaFold 4. The model excels at predicting protein-drug binding and has secured billion-dollar deals with J&J, Eli Lilly, and Novartis.
Google DeepMind spinoff Isomorphic Labs revealed IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy. It reduces drug discovery timelines from years to months, transforming pharmaceutical R&D.